NVAX
Price
$9.46
Change
+$0.34 (+3.73%)
Updated
Nov 5, 04:00 PM (EDT)
One day until earnings call
PGEN
Price
$0.82
Change
+$0.01 (+1.23%)
Updated
Nov 5, 04:00 PM (EDT)
7 days until earnings call
Ad is loading...

NVAX vs PGEN

Header iconNVAX vs PGEN Comparison
Open Charts NVAX vs PGENBanner chart's image
Novavax
Price$9.46
Change+$0.34 (+3.73%)
Volume$403.61K
CapitalizationN/A
Precigen
Price$0.82
Change+$0.01 (+1.23%)
Volume$112.67K
CapitalizationN/A
View a ticker or compare two or three
NVAX vs PGEN Comparison Chart
Loading...
NVAX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
NVAX vs. PGEN commentary
Nov 05, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVAX is a Hold and PGEN is a Hold.

COMPARISON
Comparison
Nov 05, 2024
Stock price -- (NVAX: $9.12 vs. PGEN: $0.81)
Brand notoriety: NVAX: Notable vs. PGEN: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVAX: 63% vs. PGEN: 90%
Market capitalization -- NVAX: $1.46B vs. PGEN: $237.86M
NVAX [@Biotechnology] is valued at $1.46B. PGEN’s [@Biotechnology] market capitalization is $237.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $498.83B to $0. The average market capitalization across the [@Biotechnology] industry is $2.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVAX’s FA Score shows that 0 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • NVAX’s FA Score: 0 green, 5 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, both NVAX and PGEN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVAX’s TA Score shows that 3 TA indicator(s) are bullish while PGEN’s TA Score has 4 bullish TA indicator(s).

  • NVAX’s TA Score: 3 bullish, 6 bearish.
  • PGEN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PGEN is a better buy in the short-term than NVAX.

Price Growth

NVAX (@Biotechnology) experienced а -11.02% price change this week, while PGEN (@Biotechnology) price change was -3.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.79%. For the same industry, the average monthly price growth was +15.00%, and the average quarterly price growth was +10.61%.

Reported Earning Dates

NVAX is expected to report earnings on Mar 04, 2025.

PGEN is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (+4.79% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVAX($1.46B) has a higher market cap than PGEN($238M). NVAX YTD gains are higher at: 90.000 vs. PGEN (-39.343). PGEN has higher annual earnings (EBITDA): -130.97M vs. NVAX (-228.25M). NVAX has more cash in the bank: 1.05B vs. PGEN (19.5M). PGEN has less debt than NVAX: PGEN (6.34M) vs NVAX (233M). NVAX has higher revenues than PGEN: NVAX (560M) vs PGEN (4.39M).
NVAXPGENNVAX / PGEN
Capitalization1.46B238M613%
EBITDA-228.25M-130.97M174%
Gain YTD90.000-39.343-229%
P/E RatioN/AN/A-
Revenue560M4.39M12,759%
Total Cash1.05B19.5M5,385%
Total Debt233M6.34M3,674%
FUNDAMENTALS RATINGS
NVAX vs PGEN: Fundamental Ratings
NVAX
PGEN
OUTLOOK RATING
1..100
5056
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
96100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
5491
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a12

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PGEN's Valuation (57) in the null industry is in the same range as NVAX (87) in the Biotechnology industry. This means that PGEN’s stock grew similarly to NVAX’s over the last 12 months.

NVAX's Profit vs Risk Rating (96) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that NVAX’s stock grew similarly to PGEN’s over the last 12 months.

PGEN's SMR Rating (98) in the null industry is in the same range as NVAX (100) in the Biotechnology industry. This means that PGEN’s stock grew similarly to NVAX’s over the last 12 months.

NVAX's Price Growth Rating (54) in the Biotechnology industry is somewhat better than the same rating for PGEN (91) in the null industry. This means that NVAX’s stock grew somewhat faster than PGEN’s over the last 12 months.

NVAX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that NVAX’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVAXPGEN
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 14 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
NVAX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RLACX27.940.03
+0.11%
Russell Inv US Small Cap Equity A
ARTGX23.490.01
+0.04%
Artisan Global Value Investor
RSVYX28.63N/A
N/A
Victory RS Value Y
HDGSX37.89-0.04
-0.11%
Hartford Dividend and Growth R4
LGCAX16.70-0.02
-0.12%
Lord Abbett Global Equity A

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with BEAM. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
-0.49%
BEAM - PGEN
53%
Loosely correlated
+6.24%
CRSP - PGEN
52%
Loosely correlated
-0.28%
NTLA - PGEN
52%
Loosely correlated
+2.30%
VERV - PGEN
52%
Loosely correlated
+1.85%
INZY - PGEN
50%
Loosely correlated
+1.38%
More